From  16th to 18th April, our process specialists will be glad to present the latest developments: RheaLyo™ mono freeze-dryer: our Single Vial Unit for R&D. Fast formulation and process development. RheaLyo™ multi freeze-dryer: our machine for non-GMP stability batch productions. RheaLyo™ GMP-Flex™ production lines: for clinical and commercial productions.

Ghent University will receive up to US $1.9 million to test the performance of optimised mRNA vaccines, developed on the university’s specialised mRNA Galsomes platform, in preclinical models after ‘spin-freezing’ the vaccines. Pioneered by RheaVita, a spin-off company of Ghent University, spin-freezing is a novel alternative to the traditional freeze-drying method. The research will be supported by Flanders Institute for Biotechnology (VIB).

We have created a White Paper describing how continuous aseptic freeze-drying can address the major pain points of pharmaceutical batch freeze-drying such as: time-consuming, inefficient, energy-consuming, and poorly controlled.

Download the White Paper describing the advantages associated with a RheaVita’s NextGen continuous and controlled lyophilization.

Coriolis Pharma extends its service portfolio by integrating RheaVita’s single vial unit (SVU) technology for continuous and controlled freeze-drying to stabilize novel modalities as part of biologics drug product development for clients.

Research at Ghent University, in collaboration with The University of British Columbia, has shown that continuous freeze-drying of mRNA LNPs enables long-term storage at higher temperatures for months without losing their transfection properties